Navigation Links
China Medicine Announces Strong Second Quarter 2008 Results

Revenues increased 40.8% to $11.6 million

Net Income increased 118.8% to $2.5 million

GUANGZHOU, China, Aug. 13 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary-supplements, medical devices, and medical formulations in the People's Republic of China ("PRC"), today reported strong financial results for the second quarter ended June 30, 2008.

Second Quarter 2008 Highlights:

-- Revenues increased 40.8% to $11.6 million

-- Gross profit increased 72.8% to $4.2 million

-- Operating income increased 107% to $3.0 million

-- Net income increased 118.8% to $2.5 million, or $0.16 per diluted share

"We are pleased to report strong revenue growth driven by an increase in sales of pharmaceutical products through exclusive nationwide and regional distribution rights, competitive pricing, timely delivery of products and excellent after-sales customer service," commented Mr. Senshan Yang, Chairman and CEO of China Medicine.

Revenues for the second quarter of 2008 grew 40.8% to $11.6 million from $8.3 million in the second quarter of 2007. The increase was attributable to an overall increase in sales from the Company's pharmaceutical product portfolio. Sales of pharmaceutical products obtained though the Guangdong Sunshine Medicine Public Internet Bidding System contributed to 35% of total revenues. Sales of pharmaceutical products with national distribution rights made up 35.7% of total revenues, and sales of products with manufacturing license accounted for 5.6% of total revenues. Sales of pharmaceutical products with regional-level distribution rights made up 23.7% of total revenues.

Product sales totaled $11.1 million and accounted for 95.1% of total net revenues. 420 (15,919)

Change in operating liabilities

Accounts payable, trade 21,928 30,328

Other payables and accrued

liabilities (52,364) (67,809)

Other payables-related parties -- 30,772

Customer deposits 4,931 (157,245)

Taxes payable (371,810) 245,048

Liquidated damages payable -- 1,133

Net cash used in operating

activities (2,985,402) (3,094,478)



Deposit for patent (605,657) --

Purchase of equipment (17,226) (214,162)

Purchase of intangible asset -- (132,011)

Net cash used in investing

activities (622,883) (346,173)



Proceeds from exercise of warrants

and options 362,500 5,717,789

Net cash provided by financing

activities 362,500 5,717,789


(DECREASE) INCREASE IN CASH (2,996,315) 2,331,198

CASH, beginning of period 5,767,774 371,480

CASH, end of period $2,771,459 $2,702,678

For more information, please contact:

Company Contact:

Ms. Huizhen Yu

Chief Financial Officer

China Medicine Corp

Tel: +86-20-8739-1718


Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Investor Relations

Tel: +1-646-213-1915 (NY Office)



Sales of Western-style prescription and over-the-counter products accounted for 66.1% of total revenues for the second quarter. Sales of TCM prescription and over-the-counter products accounted for 26.9% of total revenues. Medical formula sales, which totaled $0.57 million, accounted for 4.9% of total revenues, representing an increase of 14% over the second quarter of 2007.

Gross profit in the second quarter of 2008 was $4.2 million, an increase of 72.8% over the second quarter of 2007. Gross margin increased significantly in the second quarter to 35.7% versus 29.1% for the same period in 2007, and 33.7% in the first quarter or 2008. The increase in gross margin was attributable to the Company's strategy of restructuring its product portfolio mix, which includes higher-margin prescription pharmaceutical products and less over-the-counter generic pharmaceutical products.

Operating expenses in the second quarter of 2008 were $1.2 million, up 21.5% from $0.96 million in the second quarter of 2007. The increase was due to higher selling, general and administrative expenses, but was less than the increase in revenues for the quarter. Operating expenses represented 10.0% of total revenues in the second quarter of 2008, down from 11.6% in the second quarter of 2007.

Operating income was $3.0 million in the second quarter of 2008, up 107% from $1.4 million in second quarter of 2007. Operating margin for the second quarter of 2008 was 25.7% compared to 17.5% for the second quarter of 2007.

Net income for the second quarter of 2008 was $2.5 million or $0.16 per diluted share, up 118.8% from $1.1 million, or $0.08 per diluted share in the second quarter of 2007. Earnings per share reflect an increase of 1.4 million diluted average shares compared to the second quarter of 2007, primarily due to the exercise of warrants and options.

Six Month Results

For the first half of 2008, revenues increased to $18.7 million, up 40% from $13.4 million in first half of 2007. Gross profit increased 58.1% to $6.5 million in the first six months of 2008, versus $4.1 million in the first six month of 2007. Gross margin was 34.6% in the first half of 2008 compared to 30.6% during the first half of 2007. Operating income in the first half of 2008 grew 84.3% to $4.4 million compared to $2.4 million in the first half 2007. Net income for the first six months of 2008 was $3.6 million or $0.23 per diluted share, up 92.6% from $1.9 million, or $0.15 per diluted share in the first half of 2007.

Financial Condition

As of June 30, 2008, China Medicine had approximately $34.2 million in working capital, an increase of 20% from $28.5 million as of December 31, 2007. Also as of June 30, 2008, China Medicine had $2.8 million in cash and cash equivalents, a decrease of 51.7% from $5.8 million as of December 31, 2007. For the six months ended June 30, 2008, cash used in operating activities was $2.99 million, compared to $3.1 million for the six months ended 2007. Cash used in operating activities is largely related to the Company's account receivable and advance payments to suppliers. Stockholders' equity as of June 30, 2008 was $37.0 million, an increase of 20% over the $30.9 million recorded as of December 31, 2007.

Business Outlook

China Medicine is actively expanding its product portfolio to include higher margin products in order to increase profitability. In the first half of 2008, the Company maintained distribution rights, through the Guangdong Sunshine Medicine Public Internet Bidding System, to sell all pharmaceutical products included in its current catalogue. This enables the Company to increase gross margin since it reduces expenses tied to introducing new products into the market.

During the quarter, China Medicine also achieved a major milestone in obtaining a patent for recombinant aflatoxin-detoxifizyme (rADTZ) in Australia that is valid through January 13, 2025. This is in addition to a patent granted in early 2004 from State Intellectual Property Office of China. The Company has applied for rADTZ patents in 13 different jurisdictions in 2007 (including Australia, Canada, the European Union, Indonesia, Israel, Japan, South Korea, Mexico, Russia, South Africa, the U.S., Hong Kong and India). China Medicine is currently testing rADTZ on animal feed and is scheduled to begin working with the Chinese Department of Agriculture on a large scale experiment in order to meet national standards and apply for production permits. Due to the 2008 Beijing Olympics Games, the application for a production permit will be delayed since the Chinese government mandated that all toxic tests and experiments be temporarily halted before and during the Olympics. Therefore, further testing on rADTZ will be suspended for approximately three months.

To date, the Company has been approached by potential customers for rADTZ, including a large scale chicken farm in Guangzhou Province; a leading international provider of food, agriculture and risk management products and services; and an international manufacturer of enzymes for the detergent, textile, and food and feed industries. "The entrance of rADTZ in the animal feed industry is relatively easy since we will only need approval from the Department of Agriculture in China, which is in contrast to entering the food industry, where the process might take years," said Mr. Yang. "Therefore, our target market is China's entire feed industry, which is approximately RMB 274.2 billion ($39.8 billion, 1 RMB = $0.145). In the next three years, we hope rADTZ will capture 20% of the animal feed market," said Mr. Yang.

"Based on our outstanding first half 2008 performance, we feel confident that we will meet our guidance of 25%-35% revenue growth and 30%-35% gross margins for fiscal 2008. In addition, based on our strong second quarter profitability, we expect to exceed our net income guidance of 20%-22% for 2008," concluded Mr. Yang.

Conference Call

China Medicine will hold its second quarter conference call for all interested persons at 10:00 a.m. Eastern Time on August 13, 2008 to discuss its results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888.482.0024. International callers should dial 617.801.9702. When prompted by the operator, mention conference passcode 38093968. If you are unable to participate in the call at its scheduled time, a replay will be available for seven days starting on Wednesday, August 13 at 12:00 p.m. Eastern Time. To access the replay, dial 888-286-8010 (international callers dial 617-801-6888), and enter the passcode 73037488.

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company that discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over-the-counter drugs, traditional Chinese medicine products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces and to more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website a t .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward- looking statement to reflect events or circumstances after the date of this release.


Three months ended Six months ended

June, 30 June, 30

2008 2007 2008 2007


Product sales $11,067,074 $7,764,535 $17,918,458 $12,647,744

Medical formula sales 570,465 499,433 780,120 709,219

Total revenues 11,637,539 8,263,968 18,698,578 13,356,963

COST OF GOOD SOLD 7,481,170 5,859,008 12,230,189 9,264,425

GROSS PROFIT 4,156,369 2,404,960 6,468,389 4,092,538


Research and

development 107,824 543 196,216 100,655

Selling, general and

administrative 1,060,082 960,924 1,872,590 1,604,770

Total operating

expenses 1,167,906 961,467 2,068,806 1,705,425

INCOME FROM OPERATIONS 2,988,463 1,443,493 4,399,583 2,387,113


NET 32,104 (7,118) 38,087 (10,090)



INTEREST 3,020,567 1,436,375 4,437,670 2,377,023


TAXES 572,176 338,326 840,943 538,285


INTEREST 2,448,391 1,098,049 3,596,727 1,838,738

MINORITY INTEREST 17,833 29,085 45,310 52,117

NET INCOME 2,466,224 1,127,134 3,642,037 1,890,855



Foreign currency


adjustment 744,658 559,325 2,071,824 559,325

COMPREHENSIVE INCOME $3,210,882 $1,686,459 $5,713,861 $2,450,180


Basic $0.16 $0.09 $0.24 $0.18

Diluted 0.16 0.08 0.23 0.15



Basic 15,206,124 12,160,111 15,118,595 10,692,414

Diluted 15,634,713 14,232,457 15,547,183 12,764,759



AS OF JUNE 30, 2008 AND DECEMBER 31, 2007


2008 2007



Cash $2,771,459 $5,767,774

Accounts receivable, trade, net of

allowance for doubtful accounts

of $59,212 and $55,640 as of June

30, 2008 and December 31, 2007,

respectively 15,176,874 13,626,347

Notes receivables 1,718,702 --

Inventories 5,029,693 3,948,460

Advances to suppliers 9,937,629 5,983,277

Other current assets 86,003 81,221

Total current assets 34,720,360 29,407,079

EQUIPMENT, net 1,296,716 1,388,919


Deferred expenses 541,328 678,237

Deposit for patent 622,993 --

Intangible assets, net 1,240,804 1,166,003

Total other assets 2,405,125 1,844,240

Total assets $38,422,201 $32,640,238


S H A R E H O L D E R S' E Q U I T Y


Accounts payable, trade $104,401 $76,907

Other payables and accrued

liabilities 19,686 70,343

Customer deposits 221,401 203,281

Taxes payable 115,782 468,184

Liquidated damages payable 44,003 44,003

Total liabilities 505,273 862,718

MINORITY INTEREST 904,070 893,337


Preferred stock, $0.0001 par value;

10,000,000 shares authorized,

- and 111,649 shares issued and

outstanding at June 30, 2008 and

December 31, 2007, respectively -- 11

Common stock, $0.0001 par value;

100,000,000 shares authorized,

15,226,742 and 14,821,641 shares

issued and outstanding at June 30,

2008 and December 31, 2007,

respectively 1,522 1,482

Paid-in capital 12,974,863 12,560,078

Statutory reserves 2,191,230 2,191,230

Retained earnings 17,650,624 14,008,587

Accumulated other comprehensive

income 4,194,619 2,122,795

Total shareholders' equity 37,012,858 30,884,183

Total liabilities and

shareholders' equity $38,422,201 $32,640,238





2008 2007



Net income $3,642,037 $1,890,855

Adjustments to reconcile net income

to cash used in operating activities:

Minority interest (45,310) (52,117)

Depreciation and amortization 193,572 130,330

Bad debt expense -- 876

Stock issued for services -- 134,550

Amortization of stock option and

warrant compensation 52,314 50,258

Amortization of deferred expenses 175,421 --

Loss on currency exchange -- 19,620

Change in operating assets

Accounts receivable, trade (657,089) 521,256

Notes receivables (1,670,875) --

Inventories (804,759) (2,500,265)

Advances to suppliers (3,473,818) (3,356,149)

Other current assets

SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
Breaking Biology News(10 mins):